secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021199
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q1 net loss $30.2M ($0.74/sh); cash $256.2M; evorpacept trials advance
--------------------------------------------------------------------------------

- GAAP net loss $30.2M vs $24.5M YoY; non-GAAP net loss $23.8M vs $19.0M.
- Cash, equivalents and investments $256.2M; runway through mid-2025 with $40M term loan available.
- R&D expenses $24.8M, up 45% YoY driven by more active trials and manufacturing.
- Entered clinical collaboration with Sanofi to test evorpacept + SARCLISA in relapsed/refractory multiple myeloma.
- Top-line data expected H2 2023 from ASPEN-06 (gastric cancer) and ASPEN-02 (MDS) trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023021199/0000950170-23-021199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023021199/alxo-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer